MedTrace Logo

Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.

NCT01956903 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2013-10-08

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of sequential infusion of allogenic mesenchymal stem cells (MSC) expanded "in vitro" in treating patients with acute graft-versus-host disease refractory to first-line therapy.

Conditions

  • Chronic Graft-Versus-Host Disease

Interventions

GENETIC

Allogenic Mesenchymal Stem Cell

Expanded in-Vitro Allogenic Mesenchymal Stem Cell (authorized by Spain, "Agencia Española de Medicamentos y Productos Sanitarios" with number 06-076)

Sponsors & Collaborators

  • Grupo Espanol de trasplantes hematopoyeticos y terapia celular

    lead OTHER

Principal Investigators

  • Fermín M Sánchez Guijo, MD · Hospital Universitario de Salamanca, Salamanca. Spain.

  • Felipe Prosper, MD · Clínica Universitaria de Navarra, Spain.

  • Eduardo Olavarría, MD · Hospital de Navarra, Spain

  • Rocío Parody, MD · Hospital Universitario Virgen del Rocío, Seville, Spain.

  • Carmen Regidor, MD · Hospital Universitario Puerta del Hierro, Spain

  • Carmen Martínez, MD · Hospital Clinic i Provincial de Barcelona, Spain

  • Rodrigo Martino, MD · Hospital de la Santa Creu i Sant Pau, Spain

  • José Antonio Pérez-Simón, MD · Hospital Universitario Virgen del Rocío, Seville, Spain.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01956903 on ClinicalTrials.gov